(Not giving up) the marathon race of Met targeting therapy: Are we there yet?

Research output: Contribution to journalArticle

Abstract

Among the various MET aberrations, MET amplification and METex14 have emerged as valid predictive biomarkers for MET inhibition. Despite challenges that have limited the development of MET inhibitors, we can learn from the latest efforts in biomarker-based therapy to better identify the patients who will benefit from treatment with these agents.

Original languageEnglish (US)
Pages (from-to)2375-2378
Number of pages4
JournalClinical Cancer Research
Volume25
Issue number8
DOIs
StatePublished - Apr 15 2019

Fingerprint

Biomarkers
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{c9ef7bab635b4bf191dda9c05e653c55,
title = "(Not giving up) the marathon race of Met targeting therapy: Are we there yet?",
abstract = "Among the various MET aberrations, MET amplification and METex14 have emerged as valid predictive biomarkers for MET inhibition. Despite challenges that have limited the development of MET inhibitors, we can learn from the latest efforts in biomarker-based therapy to better identify the patients who will benefit from treatment with these agents.",
author = "Ma, {Patrick Chi-Chung}",
year = "2019",
month = "4",
day = "15",
doi = "10.1158/1078-0432.CCR-18-3739",
language = "English (US)",
volume = "25",
pages = "2375--2378",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

(Not giving up) the marathon race of Met targeting therapy : Are we there yet? / Ma, Patrick Chi-Chung.

In: Clinical Cancer Research, Vol. 25, No. 8, 15.04.2019, p. 2375-2378.

Research output: Contribution to journalArticle

TY - JOUR

T1 - (Not giving up) the marathon race of Met targeting therapy

T2 - Are we there yet?

AU - Ma, Patrick Chi-Chung

PY - 2019/4/15

Y1 - 2019/4/15

N2 - Among the various MET aberrations, MET amplification and METex14 have emerged as valid predictive biomarkers for MET inhibition. Despite challenges that have limited the development of MET inhibitors, we can learn from the latest efforts in biomarker-based therapy to better identify the patients who will benefit from treatment with these agents.

AB - Among the various MET aberrations, MET amplification and METex14 have emerged as valid predictive biomarkers for MET inhibition. Despite challenges that have limited the development of MET inhibitors, we can learn from the latest efforts in biomarker-based therapy to better identify the patients who will benefit from treatment with these agents.

UR - http://www.scopus.com/inward/record.url?scp=85064746425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064746425&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-18-3739

DO - 10.1158/1078-0432.CCR-18-3739

M3 - Article

C2 - 30770350

AN - SCOPUS:85064746425

VL - 25

SP - 2375

EP - 2378

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 8

ER -